Immunogenetic and phenotypic features in HCL
. | Immunoglobulin expression* . | . | . | . | . | . | VH gene status . | . | . | . | . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case . | IgM . | IgD . | IgG . | IgA . | VH . | % homology† . | JH . | D . | No. tumor-derived clones/total no. clones . | Intraclonal heterogeneity‡ . | AID . | CD27 . | CD38 . | ||||||||
| 42 | + | + | + | − | 3-33 | 93.5 | 4b | 6-13 | 8/10 | + | + (wt) + (Ex4) | − | − | ||||||||
| 83 | + | + | + | − | 3-23 | 97.6 | 4b | 2-21 | 8/8 | + | + (wt) + (Ex4) | − | − | ||||||||
| 93 | + | + | + | − | 3-33 | 96.9 | 6b | 4-11 | 7/8 | + | + (wt) + (Ex4) | − | − | ||||||||
| E70 | + | + | + | − | 4-59 | 97.2 | 2 | 1-26 | 4/4 | − | + (wt) + (Ex4) | − | − | ||||||||
| G13 | − | + | + | − | 3-30 | 100 | 4b | 6-19 | 10/10 | − | + (wt) + (Ex4) | − | − | ||||||||
| 206 | + | + | + | − | 3-23 | 91.4 | 4b | 6-25 | 12/12 | + | Neg | − | − | ||||||||
| 216 | − | + | + | + | 3-23 | 94.9 | 4b | 4-17 | 10/10 | + | + (wt) + (Ex4) | − | − | ||||||||
| 266 | + | + | + | − | 1-02 | 95.9 | 2 | 1-14 | 9/9 | + | + (wt) + (Ex4) | − | − | ||||||||
| 283 | + | + | + | − | 3-30 | 100 | 4b | 4-17 | 10/10 | − | + (wt) | − | − | ||||||||
. | Immunoglobulin expression* . | . | . | . | . | . | VH gene status . | . | . | . | . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case . | IgM . | IgD . | IgG . | IgA . | VH . | % homology† . | JH . | D . | No. tumor-derived clones/total no. clones . | Intraclonal heterogeneity‡ . | AID . | CD27 . | CD38 . | ||||||||
| 42 | + | + | + | − | 3-33 | 93.5 | 4b | 6-13 | 8/10 | + | + (wt) + (Ex4) | − | − | ||||||||
| 83 | + | + | + | − | 3-23 | 97.6 | 4b | 2-21 | 8/8 | + | + (wt) + (Ex4) | − | − | ||||||||
| 93 | + | + | + | − | 3-33 | 96.9 | 6b | 4-11 | 7/8 | + | + (wt) + (Ex4) | − | − | ||||||||
| E70 | + | + | + | − | 4-59 | 97.2 | 2 | 1-26 | 4/4 | − | + (wt) + (Ex4) | − | − | ||||||||
| G13 | − | + | + | − | 3-30 | 100 | 4b | 6-19 | 10/10 | − | + (wt) + (Ex4) | − | − | ||||||||
| 206 | + | + | + | − | 3-23 | 91.4 | 4b | 6-25 | 12/12 | + | Neg | − | − | ||||||||
| 216 | − | + | + | + | 3-23 | 94.9 | 4b | 4-17 | 10/10 | + | + (wt) + (Ex4) | − | − | ||||||||
| 266 | + | + | + | − | 1-02 | 95.9 | 2 | 1-14 | 9/9 | + | + (wt) + (Ex4) | − | − | ||||||||
| 283 | + | + | + | − | 3-30 | 100 | 4b | 4-17 | 10/10 | − | + (wt) | − | − | ||||||||
+ (wt) indicates wild-type AID transcript identified as a 570 bp band after amplification by RT-PCR; + (Ex4), identification of AID splice variant transcript with loss of exon 4 (454 bp).
Expression for each isotype was defined as positive (+) when mean fluorescence intensity was higher than 1.5. Expression of each isotype was determined on the CD19/CD11c HCs.17 Within the HCs, there was no evidence for subpopulations, with the majority of tumor events expressing each isotype.
Homology to closest germ line VH gene.
Intraclonal heterogeneity was defined as previously described.17 VH gene data on cases 42, 83, and 93 were reported previously.17